Seshadri Neervannan, Ph.D.

Seshadri Neervannan, Ph.D.

Chief Operating OfficeratTarsus Pharmaceuticals· In proxies 2023–2025

Pay in FY2025-18% from the year before · Tarsus Pharmaceuticals stock +47.9% the same year

Seshadri Neervannan, Ph.D. was paid $2.6M in FY2025 (Dec), down 18%. Tarsus Pharmaceuticals stock rose 47.9% that year.

Pay$100 in the stock at the end of FY22 → $559
Pay is from the Summary Compensation Table of each Tarsus Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Tarsus PharmaceuticalsPublic company · 3 yr
    • Chief Operating Officer2023 – Present · 3 yrStock in role +407%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?